Pharma facing up to new role as driver of better diagnostics

Every drug developer with ambitions to be part of the precision medicine revolution knows that improved detection rates are key to treating diseases earlier and more effectively.

In some cases, they know that the viability of the treatments that they are developing, depends on diagnostics improving, even if they may not currently have direct control over the latter.

On the other hand, there are instances where companies are investing in the diagnostic side when they have no guarantee that their candidate will reach market, adding further cost and risk to drug development.